Q1 2011 Earnings Call

May 05, 2011 04:30 pm ET


Carol DeGuzman - Senior Director, IR

Steven Engle - Chairman & CEO

Fred Kurland - VP & CFO

Alan Solinger - VP of Clinical Immunology


Christopher James - McNicoll, Lewis, & Vlak

Richard Lau - Wedbush Securities

Matt Kaplan - Ladenburg Thalmann & Co.

Ritu Baral - Canaccord Genuity

Adnan Butt - RBC Capital Markets



Good day ladies and gentlemen. And welcome to XOMA’s First Quarter 2011 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator instructions) And as a reminder, this conference call may be recorded.

At this time I’d like to hand the conference over to Ms. Carol DeGuzman, Senior Director of Investor Relations. Ma'am you may begin.

Carol DeGuzman

Thank you operator. Good afternoon and welcome to today’s call. A short while ago, we issued a news release, which included our financial results for the quarter ended March 31, 2011, and a general business update. Our quarterly report on Form 10-Q was filed with the Securities and Exchange Commission this afternoon. Each document will be available on the XOMA website.

Today’s webcast also can be accessed via our website and will be available for replay until the close of business on July 5, 2011. Joining me on today’s call is Steven Engle, Chairman and Chief Executive Officer and Fred Kurland our Vice President and Chief Financial Officer and Dr. Alan Solinger, our Vice President of Clinical Immunology.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million